A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT03410992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study identification
- NCT ID
- NCT03410992
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 435 participants
Conditions and interventions
Interventions
- Bimekizumab Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2018
- Primary completion
- Dec 27, 2018
- Completion
- Jan 6, 2020
- Last update posted
- Apr 14, 2026
2018 – 2020
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0013 919 | San Diego | California | 92103 | — |
| Ps0013 955 | San Diego | California | 92123 | — |
| Ps0013 967 | Santa Monica | California | 90404 | — |
| Ps0013 928 | Fort Myers | Florida | 33912 | — |
| Ps0013 966 | Sandy Springs | Georgia | 30329 | — |
| Ps0013 954 | Skokie | Illinois | 60077 | — |
| Ps0013 962 | Owensboro | Kentucky | 42303 | — |
| Ps0013 944 | New Orleans | Louisiana | 70115 | — |
| Ps0013 940 | Beverly | Massachusetts | 01915 | — |
| Ps0013 901 | Portsmouth | New Hampshire | 03801 | — |
| Ps0013 956 | Verona | New Jersey | 07044-2946 | — |
| Ps0013 947 | Buffalo | New York | 14221 | — |
| Ps0013 968 | New York | New York | 10021 | — |
| Ps0013 965 | New York | New York | 10025 | — |
| Ps0013 963 | Rochester | New York | 14623 | — |
| Ps0013 949 | Cleveland | Ohio | 44106-1716 | — |
| Ps0013 929 | Portland | Oregon | 97223 | — |
| Ps0013 937 | Johnston | Rhode Island | 02919 | — |
| Ps0013 914 | San Antonio | Texas | 78213 | — |
| Ps0013 933 | Murray | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03410992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03410992 live on ClinicalTrials.gov.